CN120225225A - 去泛素化酶靶向性嵌合体及相关方法 - Google Patents
去泛素化酶靶向性嵌合体及相关方法 Download PDFInfo
- Publication number
- CN120225225A CN120225225A CN202280032073.1A CN202280032073A CN120225225A CN 120225225 A CN120225225 A CN 120225225A CN 202280032073 A CN202280032073 A CN 202280032073A CN 120225225 A CN120225225 A CN 120225225A
- Authority
- CN
- China
- Prior art keywords
- tautomer
- stereoisomer
- solvate
- pharmaceutically acceptable
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181796P | 2021-04-29 | 2021-04-29 | |
| US63/181,796 | 2021-04-29 | ||
| US202163186739P | 2021-05-10 | 2021-05-10 | |
| US63/186,739 | 2021-05-10 | ||
| US202163273118P | 2021-10-28 | 2021-10-28 | |
| US63/273,118 | 2021-10-28 | ||
| US202263311781P | 2022-02-18 | 2022-02-18 | |
| US63/311,781 | 2022-02-18 | ||
| PCT/US2022/027120 WO2022232634A1 (en) | 2021-04-29 | 2022-04-29 | Deubiquitinase-targeting chimeras and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120225225A true CN120225225A (zh) | 2025-06-27 |
Family
ID=81748638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280032073.1A Pending CN120225225A (zh) | 2021-04-29 | 2022-04-29 | 去泛素化酶靶向性嵌合体及相关方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252655A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329815A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024515828A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240004584A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120225225A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022265718A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022315A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216614A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307863A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012852A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232634A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220874A2 (en) * | 2023-04-21 | 2024-10-24 | Icahn School Of Medicine At Mount Sinai | Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs) |
| WO2024233280A1 (en) * | 2023-05-05 | 2024-11-14 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7 |
| WO2024264072A2 (en) * | 2023-06-23 | 2024-12-26 | Stablix, Inc. | Parp inhibitors |
| CN119350422B (zh) * | 2024-12-25 | 2025-04-04 | 中国药科大学 | 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008109031A (ru) | 2005-08-11 | 2009-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы муковисцидозного трансмембранного регулятора проводимости |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| US20110035601A1 (en) | 2007-12-21 | 2011-02-10 | University Of Virginia Patent Foundation | System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms |
| EP2303885B1 (en) | 2008-06-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Process for producing bicycloaniline derivatives |
| CZ2009620A3 (cs) | 2009-09-22 | 2011-04-06 | Ústav makromolekulární chemie AV CR, v.v.i. | Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| KR20150097660A (ko) | 2012-12-19 | 2015-08-26 | 노파르티스 아게 | Cftr 채널을 억제하기 위한 트리시클릭 화합물 |
| CA2895656A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| WO2018037350A1 (en) | 2016-08-23 | 2018-03-01 | Laurus Labs Limited | Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof |
| CA3103205A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting uchl5 |
| WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
| EP4090371A4 (en) * | 2020-01-14 | 2024-04-03 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES |
-
2022
- 2022-04-29 CA CA3216614A patent/CA3216614A1/en active Pending
- 2022-04-29 AU AU2022265718A patent/AU2022265718A1/en active Pending
- 2022-04-29 KR KR1020237040245A patent/KR20240004584A/ko active Pending
- 2022-04-29 IL IL307863A patent/IL307863A/en unknown
- 2022-04-29 BR BR112023022315A patent/BR112023022315A2/pt unknown
- 2022-04-29 US US18/288,550 patent/US20240252655A1/en active Pending
- 2022-04-29 WO PCT/US2022/027120 patent/WO2022232634A1/en not_active Ceased
- 2022-04-29 JP JP2023566513A patent/JP2024515828A/ja active Pending
- 2022-04-29 EP EP22724358.1A patent/EP4329815A1/en active Pending
- 2022-04-29 CN CN202280032073.1A patent/CN120225225A/zh active Pending
- 2022-04-29 MX MX2023012852A patent/MX2023012852A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329815A1 (en) | 2024-03-06 |
| CA3216614A1 (en) | 2022-11-03 |
| MX2023012852A (es) | 2024-01-15 |
| US20240252655A1 (en) | 2024-08-01 |
| WO2022232634A1 (en) | 2022-11-03 |
| JP2024515828A (ja) | 2024-04-10 |
| BR112023022315A2 (pt) | 2024-02-20 |
| IL307863A (en) | 2023-12-01 |
| AU2022265718A1 (en) | 2023-11-02 |
| KR20240004584A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7005582B2 (ja) | ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物 | |
| US20240252655A1 (en) | Deubiquitinase-targeting chimeras and related methods | |
| RU2687060C2 (ru) | Фармацевтические соединения | |
| CN114057771B (zh) | 大环化合物及其制备方法和应用 | |
| EP3569602B1 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
| EP3398950B1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
| KR20130008557A (ko) | Cdk4/6의 억제제로서의 중수소화 피롤로피리미딘 화합물 | |
| US20200289659A1 (en) | Conjugates for treating diseases | |
| RU2632199C2 (ru) | Функционализированные производные тиеноиндола для лечения ракового заболевания | |
| AU2020255702B2 (en) | Quinolyl-containing compound and pharmaceutical composition, and use thereof | |
| CN121909188A (zh) | 一类nsd蛋白降解剂及其用途 | |
| US20190084988A1 (en) | Wdr5 inhibitors and modulators | |
| CN112243437A (zh) | 含丙烯酰基的核转运调节剂及其用途 | |
| WO2024220852A2 (en) | Tead core inhibitors for cancer therapeutics | |
| KR102938808B1 (ko) | Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도 | |
| CN112341390A (zh) | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 | |
| US20250082657A1 (en) | Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof | |
| US10590101B2 (en) | Benzo-N-hydroxy amide compounds having antitumor activity | |
| EP4556465A1 (en) | Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof | |
| US20250188062A1 (en) | Triazine compounds and methods of making and using the same | |
| WO2024097355A1 (en) | Deubiquitinase-targeting chimeras and related methods | |
| US20250066353A1 (en) | Vanin-1 inhibitors | |
| Calder et al. | The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat | |
| EP4653442A1 (en) | Polycyclic compound for treating neurological diseases and tumors | |
| HK40120533A (en) | Btk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |